Pacira BioSciences (PCRX) Announces Settlement of U.S. Patent Litigation for EXPAREL
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
Pacira BioSciences Announces Settlement of U.S. Patent Litigation for EXPAREL
April 7, 2025 4:30 PM EDT-- Fresenius Kabi licensed to sell volume-limited amounts of generic bupivacaine liposome injectable suspension in the U.S. no earlier than a confidential date in 2030 --
-- Fresenius also licensed to sell generic bupivacaine liposome injectable suspension in the U.S. without volume limitations beginning in 2039 --
BRISBANE, Calif., April 07, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it has settled its litigations with Fresenius Kabi USA,... More
